http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 07 May 2026 07:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Curative+Biotechnology+Advances+Translational+Ophthalmology+Program+Through+PennVet+Research+Agreement/26447895.html <p align="justify"><i>PennVet Study to Evaluate GMP-Grade Metformin Eye Drops in a Canine Model Supporting Human and Veterinary Development Pathways</i></p> <p align="justify"><strong>Palm Beach Gardens, FL, May 07, 2026 (GLOBE NEWSWIRE) -- </strong>Curative Biotechnology, Inc. (OTC: CUBT) (“Curative” or the “Company”), a development-stage biomedical company focused on novel therapies for degenerative eye diseases, today announced that it has entered into a Sponsored Research Agreement with the University of Pennsylvania’s School of Veterinary Medicine (“PennVet”) to support a K9 study evaluating its metformin-based topical ophthalmic formulation (eye drops).</p> <p align="justify">The study will be led by Dr. Valérie L. Dufour, http://www.streetinsider.com/Press+Releases/Curative+Biotechnology+Advances+Translational+Ophthalmology+Program+Through+PennVet+Research+Agreement/26447895.html Thu, 07 May 2026 07:00:00 -0400 A.19655944 A.25657929 CUBT CUBT CUBTD O.03307993 O.35165445 O.50535763 http://www.streetinsider.com/Press+Releases/Curative+Biotechnology+Advances+Translational+Ophthalmology+Program+Through+PennVet+Research+Agreement/26447895.html <p align="justify"><i>PennVet Study to Evaluate GMP-Grade Metformin Eye Drops in a Canine Model Supporting Human and Veterinary Development Pathways</i></p> <p align="justify"><strong>Palm Beach Gardens, FL, May 07, 2026 (GLOBE NEWSWIRE) -- </strong>Curative Biotechnology, Inc. (OTC: CUBT) (“Curative” or the “Company”), a development-stage biomedical company focused on novel therapies for degenerative eye diseases, today announced that it has entered into a Sponsored Research Agreement with the University of Pennsylvania’s School of Veterinary Medicine (“PennVet”) to support a K9 study evaluating its metformin-based topical ophthalmic formulation (eye drops).</p> <p align="justify">The study will be led by Dr. Valérie L. Dufour, http://www.streetinsider.com/Press+Releases/Curative+Biotechnology+Advances+Translational+Ophthalmology+Program+Through+PennVet+Research+Agreement/26447895.html Thu, 07 May 2026 07:00:00 -0400 A.19655944 A.25657929 CUBT CUBT CUBTD O.03307993 O.35165445 O.50535763 http://www.streetinsider.com/Press+Releases/Curative+Biotechnology+Advances+Translational+Ophthalmology+Program+Through+PennVet+Research+Agreement/26447895.html <p align="justify"><i>PennVet Study to Evaluate GMP-Grade Metformin Eye Drops in a Canine Model Supporting Human and Veterinary Development Pathways</i></p> <p align="justify"><strong>Palm Beach Gardens, FL, May 07, 2026 (GLOBE NEWSWIRE) -- </strong>Curative Biotechnology, Inc. (OTC: CUBT) (“Curative” or the “Company”), a development-stage biomedical company focused on novel therapies for degenerative eye diseases, today announced that it has entered into a Sponsored Research Agreement with the University of Pennsylvania’s School of Veterinary Medicine (“PennVet”) to support a K9 study evaluating its metformin-based topical ophthalmic formulation (eye drops).</p> <p align="justify">The study will be led by Dr. Valérie L. Dufour, http://www.streetinsider.com/Press+Releases/Curative+Biotechnology+Advances+Translational+Ophthalmology+Program+Through+PennVet+Research+Agreement/26447895.html Thu, 07 May 2026 07:00:00 -0400 A.19655944 A.25657929 CUBT CUBT CUBTD O.03307993 O.35165445 O.50535763 http://www.streetinsider.com/Press+Releases/Curative+Biotechnology+Advances+Translational+Ophthalmology+Program+Through+PennVet+Research+Agreement/26447895.html <p align="justify"><i>PennVet Study to Evaluate GMP-Grade Metformin Eye Drops in a Canine Model Supporting Human and Veterinary Development Pathways</i></p> <p align="justify"><strong>Palm Beach Gardens, FL, May 07, 2026 (GLOBE NEWSWIRE) -- </strong>Curative Biotechnology, Inc. (OTC: CUBT) (“Curative” or the “Company”), a development-stage biomedical company focused on novel therapies for degenerative eye diseases, today announced that it has entered into a Sponsored Research Agreement with the University of Pennsylvania’s School of Veterinary Medicine (“PennVet”) to support a K9 study evaluating its metformin-based topical ophthalmic formulation (eye drops).</p> <p align="justify">The study will be led by Dr. Valérie L. Dufour, http://www.streetinsider.com/Press+Releases/Curative+Biotechnology+Advances+Translational+Ophthalmology+Program+Through+PennVet+Research+Agreement/26447895.html Thu, 07 May 2026 07:00:00 -0400 A.19655944 A.25657929 CUBT CUBT CUBTD O.03307993 O.35165445 O.50535763 http://www.streetinsider.com/Press+Releases/Curative+Biotechnology+Advances+Translational+Ophthalmology+Program+Through+PennVet+Research+Agreement/26447895.html <p align="justify"><i>PennVet Study to Evaluate GMP-Grade Metformin Eye Drops in a Canine Model Supporting Human and Veterinary Development Pathways</i></p> <p align="justify"><strong>Palm Beach Gardens, FL, May 07, 2026 (GLOBE NEWSWIRE) -- </strong>Curative Biotechnology, Inc. (OTC: CUBT) (“Curative” or the “Company”), a development-stage biomedical company focused on novel therapies for degenerative eye diseases, today announced that it has entered into a Sponsored Research Agreement with the University of Pennsylvania’s School of Veterinary Medicine (“PennVet”) to support a K9 study evaluating its metformin-based topical ophthalmic formulation (eye drops).</p> <p align="justify">The study will be led by Dr. Valérie L. Dufour, http://www.streetinsider.com/Press+Releases/Curative+Biotechnology+Advances+Translational+Ophthalmology+Program+Through+PennVet+Research+Agreement/26447895.html Thu, 07 May 2026 07:00:00 -0400 A.19655944 A.25657929 CUBT CUBT CUBTD O.03307993 O.35165445 O.50535763 http://www.streetinsider.com/Press+Releases/Curative+Biotechnology+Advances+Translational+Ophthalmology+Program+Through+PennVet+Research+Agreement/26447895.html <p align="justify"><i>PennVet Study to Evaluate GMP-Grade Metformin Eye Drops in a Canine Model Supporting Human and Veterinary Development Pathways</i></p> <p align="justify"><strong>Palm Beach Gardens, FL, May 07, 2026 (GLOBE NEWSWIRE) -- </strong>Curative Biotechnology, Inc. (OTC: CUBT) (“Curative” or the “Company”), a development-stage biomedical company focused on novel therapies for degenerative eye diseases, today announced that it has entered into a Sponsored Research Agreement with the University of Pennsylvania’s School of Veterinary Medicine (“PennVet”) to support a K9 study evaluating its metformin-based topical ophthalmic formulation (eye drops).</p> <p align="justify">The study will be led by Dr. Valérie L. Dufour, http://www.streetinsider.com/Press+Releases/Curative+Biotechnology+Advances+Translational+Ophthalmology+Program+Through+PennVet+Research+Agreement/26447895.html Thu, 07 May 2026 07:00:00 -0400 A.19655944 A.25657929 CUBT CUBT CUBTD O.03307993 O.35165445 O.50535763 http://www.streetinsider.com/Press+Releases/Curative+Biotechnology+Advances+Translational+Ophthalmology+Program+Through+PennVet+Research+Agreement/26447895.html <p align="justify"><i>PennVet Study to Evaluate GMP-Grade Metformin Eye Drops in a Canine Model Supporting Human and Veterinary Development Pathways</i></p> <p align="justify"><strong>Palm Beach Gardens, FL, May 07, 2026 (GLOBE NEWSWIRE) -- </strong>Curative Biotechnology, Inc. (OTC: CUBT) (“Curative” or the “Company”), a development-stage biomedical company focused on novel therapies for degenerative eye diseases, today announced that it has entered into a Sponsored Research Agreement with the University of Pennsylvania’s School of Veterinary Medicine (“PennVet”) to support a K9 study evaluating its metformin-based topical ophthalmic formulation (eye drops).</p> <p align="justify">The study will be led by Dr. Valérie L. Dufour, http://www.streetinsider.com/Press+Releases/Curative+Biotechnology+Advances+Translational+Ophthalmology+Program+Through+PennVet+Research+Agreement/26447895.html Thu, 07 May 2026 07:00:00 -0400 A.19655944 A.25657929 CUBT CUBT CUBTD O.03307993 O.35165445 O.50535763 http://www.streetinsider.com/Press+Releases/Curative+Biotechnology+Advances+Translational+Ophthalmology+Program+Through+PennVet+Research+Agreement/26447895.html <p align="justify"><i>PennVet Study to Evaluate GMP-Grade Metformin Eye Drops in a Canine Model Supporting Human and Veterinary Development Pathways</i></p> <p align="justify"><strong>Palm Beach Gardens, FL, May 07, 2026 (GLOBE NEWSWIRE) -- </strong>Curative Biotechnology, Inc. (OTC: CUBT) (“Curative” or the “Company”), a development-stage biomedical company focused on novel therapies for degenerative eye diseases, today announced that it has entered into a Sponsored Research Agreement with the University of Pennsylvania’s School of Veterinary Medicine (“PennVet”) to support a K9 study evaluating its metformin-based topical ophthalmic formulation (eye drops).</p> <p align="justify">The study will be led by Dr. Valérie L. Dufour, http://www.streetinsider.com/Press+Releases/Curative+Biotechnology+Advances+Translational+Ophthalmology+Program+Through+PennVet+Research+Agreement/26447895.html Thu, 07 May 2026 07:00:00 -0400 A.19655944 A.25657929 CUBT CUBT CUBTD O.03307993 O.35165445 O.50535763 http://www.streetinsider.com/Globe+Newswire/Curative+Biotechnology+Advances+Translational+Ophthalmology+Program+Through+PennVet+Research+Agreement/26447895.html <p align="justify"><i>PennVet Study to Evaluate GMP-Grade Metformin Eye Drops in a Canine Model Supporting Human and Veterinary Development Pathways</i></p> <p align="justify"><strong>Palm Beach Gardens, FL, May 07, 2026 (GLOBE NEWSWIRE) -- </strong>Curative Biotechnology, Inc. (OTC: CUBT) (“Curative” or the “Company”), a development-stage biomedical company focused on novel therapies for degenerative eye diseases, today announced that it has entered into a Sponsored Research Agreement with the University of Pennsylvania’s School of Veterinary Medicine (“PennVet”) to support a K9 study evaluating its metformin-based topical ophthalmic formulation (eye drops).</p> <p align="justify">The study will be led by Dr. Valérie L. Dufour, http://www.streetinsider.com/Globe+Newswire/Curative+Biotechnology+Advances+Translational+Ophthalmology+Program+Through+PennVet+Research+Agreement/26447895.html Thu, 07 May 2026 07:00:00 -0400 A.19655944 A.25657929 CUBT CUBT CUBTD O.03307993 O.35165445 O.50535763 http://www.streetinsider.com/Globe+Newswire/Curative+Biotechnology+Advances+Translational+Ophthalmology+Program+Through+PennVet+Research+Agreement/26447895.html <p align="justify"><i>PennVet Study to Evaluate GMP-Grade Metformin Eye Drops in a Canine Model Supporting Human and Veterinary Development Pathways</i></p> <p align="justify"><strong>Palm Beach Gardens, FL, May 07, 2026 (GLOBE NEWSWIRE) -- </strong>Curative Biotechnology, Inc. (OTC: CUBT) (“Curative” or the “Company”), a development-stage biomedical company focused on novel therapies for degenerative eye diseases, today announced that it has entered into a Sponsored Research Agreement with the University of Pennsylvania’s School of Veterinary Medicine (“PennVet”) to support a K9 study evaluating its metformin-based topical ophthalmic formulation (eye drops).</p> <p align="justify">The study will be led by Dr. Valérie L. Dufour, http://www.streetinsider.com/Globe+Newswire/Curative+Biotechnology+Advances+Translational+Ophthalmology+Program+Through+PennVet+Research+Agreement/26447895.html Thu, 07 May 2026 07:00:00 -0400 A.19655944 A.25657929 CUBT CUBT CUBTD O.03307993 O.35165445 O.50535763 http://www.streetinsider.com/Globe+Newswire/Curative+Biotechnology+Advances+Translational+Ophthalmology+Program+Through+PennVet+Research+Agreement/26447895.html <p align="justify"><i>PennVet Study to Evaluate GMP-Grade Metformin Eye Drops in a Canine Model Supporting Human and Veterinary Development Pathways</i></p> <p align="justify"><strong>Palm Beach Gardens, FL, May 07, 2026 (GLOBE NEWSWIRE) -- </strong>Curative Biotechnology, Inc. (OTC: CUBT) (“Curative” or the “Company”), a development-stage biomedical company focused on novel therapies for degenerative eye diseases, today announced that it has entered into a Sponsored Research Agreement with the University of Pennsylvania’s School of Veterinary Medicine (“PennVet”) to support a K9 study evaluating its metformin-based topical ophthalmic formulation (eye drops).</p> <p align="justify">The study will be led by Dr. Valérie L. Dufour, http://www.streetinsider.com/Globe+Newswire/Curative+Biotechnology+Advances+Translational+Ophthalmology+Program+Through+PennVet+Research+Agreement/26447895.html Thu, 07 May 2026 07:00:00 -0400 A.19655944 A.25657929 CUBT CUBT CUBTD O.03307993 O.35165445 O.50535763 http://www.streetinsider.com/Globe+Newswire/Curative+Biotechnology+Advances+Translational+Ophthalmology+Program+Through+PennVet+Research+Agreement/26447895.html <p align="justify"><i>PennVet Study to Evaluate GMP-Grade Metformin Eye Drops in a Canine Model Supporting Human and Veterinary Development Pathways</i></p> <p align="justify"><strong>Palm Beach Gardens, FL, May 07, 2026 (GLOBE NEWSWIRE) -- </strong>Curative Biotechnology, Inc. (OTC: CUBT) (“Curative” or the “Company”), a development-stage biomedical company focused on novel therapies for degenerative eye diseases, today announced that it has entered into a Sponsored Research Agreement with the University of Pennsylvania’s School of Veterinary Medicine (“PennVet”) to support a K9 study evaluating its metformin-based topical ophthalmic formulation (eye drops).</p> <p align="justify">The study will be led by Dr. Valérie L. Dufour, http://www.streetinsider.com/Globe+Newswire/Curative+Biotechnology+Advances+Translational+Ophthalmology+Program+Through+PennVet+Research+Agreement/26447895.html Thu, 07 May 2026 07:00:00 -0400 A.19655944 A.25657929 CUBT CUBT CUBTD O.03307993 O.35165445 O.50535763 http://www.streetinsider.com/Globe+Newswire/Curative+Biotechnology+Advances+Translational+Ophthalmology+Program+Through+PennVet+Research+Agreement/26447895.html <p align="justify"><i>PennVet Study to Evaluate GMP-Grade Metformin Eye Drops in a Canine Model Supporting Human and Veterinary Development Pathways</i></p> <p align="justify"><strong>Palm Beach Gardens, FL, May 07, 2026 (GLOBE NEWSWIRE) -- </strong>Curative Biotechnology, Inc. (OTC: CUBT) (“Curative” or the “Company”), a development-stage biomedical company focused on novel therapies for degenerative eye diseases, today announced that it has entered into a Sponsored Research Agreement with the University of Pennsylvania’s School of Veterinary Medicine (“PennVet”) to support a K9 study evaluating its metformin-based topical ophthalmic formulation (eye drops).</p> <p align="justify">The study will be led by Dr. Valérie L. Dufour, http://www.streetinsider.com/Globe+Newswire/Curative+Biotechnology+Advances+Translational+Ophthalmology+Program+Through+PennVet+Research+Agreement/26447895.html Thu, 07 May 2026 07:00:00 -0400 A.19655944 A.25657929 CUBT CUBT CUBTD O.03307993 O.35165445 O.50535763 http://www.streetinsider.com/Globe+Newswire/Curative+Biotechnology+Advances+Translational+Ophthalmology+Program+Through+PennVet+Research+Agreement/26447895.html <p align="justify"><i>PennVet Study to Evaluate GMP-Grade Metformin Eye Drops in a Canine Model Supporting Human and Veterinary Development Pathways</i></p> <p align="justify"><strong>Palm Beach Gardens, FL, May 07, 2026 (GLOBE NEWSWIRE) -- </strong>Curative Biotechnology, Inc. (OTC: CUBT) (“Curative” or the “Company”), a development-stage biomedical company focused on novel therapies for degenerative eye diseases, today announced that it has entered into a Sponsored Research Agreement with the University of Pennsylvania’s School of Veterinary Medicine (“PennVet”) to support a K9 study evaluating its metformin-based topical ophthalmic formulation (eye drops).</p> <p align="justify">The study will be led by Dr. Valérie L. Dufour, http://www.streetinsider.com/Globe+Newswire/Curative+Biotechnology+Advances+Translational+Ophthalmology+Program+Through+PennVet+Research+Agreement/26447895.html Thu, 07 May 2026 07:00:00 -0400 A.19655944 A.25657929 CUBT CUBT CUBTD O.03307993 O.35165445 O.50535763 http://www.streetinsider.com/Globe+Newswire/Curative+Biotechnology+Advances+Translational+Ophthalmology+Program+Through+PennVet+Research+Agreement/26447895.html <p align="justify"><i>PennVet Study to Evaluate GMP-Grade Metformin Eye Drops in a Canine Model Supporting Human and Veterinary Development Pathways</i></p> <p align="justify"><strong>Palm Beach Gardens, FL, May 07, 2026 (GLOBE NEWSWIRE) -- </strong>Curative Biotechnology, Inc. (OTC: CUBT) (“Curative” or the “Company”), a development-stage biomedical company focused on novel therapies for degenerative eye diseases, today announced that it has entered into a Sponsored Research Agreement with the University of Pennsylvania’s School of Veterinary Medicine (“PennVet”) to support a K9 study evaluating its metformin-based topical ophthalmic formulation (eye drops).</p> <p align="justify">The study will be led by Dr. Valérie L. Dufour, http://www.streetinsider.com/Globe+Newswire/Curative+Biotechnology+Advances+Translational+Ophthalmology+Program+Through+PennVet+Research+Agreement/26447895.html Thu, 07 May 2026 07:00:00 -0400 A.19655944 A.25657929 CUBT CUBT CUBTD O.03307993 O.35165445 O.50535763 http://www.streetinsider.com/Globe+Newswire/Curative+Biotechnology+Advances+Translational+Ophthalmology+Program+Through+PennVet+Research+Agreement/26447895.html <p align="justify"><i>PennVet Study to Evaluate GMP-Grade Metformin Eye Drops in a Canine Model Supporting Human and Veterinary Development Pathways</i></p> <p align="justify"><strong>Palm Beach Gardens, FL, May 07, 2026 (GLOBE NEWSWIRE) -- </strong>Curative Biotechnology, Inc. (OTC: CUBT) (“Curative” or the “Company”), a development-stage biomedical company focused on novel therapies for degenerative eye diseases, today announced that it has entered into a Sponsored Research Agreement with the University of Pennsylvania’s School of Veterinary Medicine (“PennVet”) to support a K9 study evaluating its metformin-based topical ophthalmic formulation (eye drops).</p> <p align="justify">The study will be led by Dr. Valérie L. Dufour, http://www.streetinsider.com/Globe+Newswire/Curative+Biotechnology+Advances+Translational+Ophthalmology+Program+Through+PennVet+Research+Agreement/26447895.html Thu, 07 May 2026 07:00:00 -0400 A.19655944 A.25657929 CUBT CUBT CUBTD O.03307993 O.35165445 O.50535763 http://www.streetinsider.com/Press+Releases/Curative+Biotechnology+Engages+Sterling+Pharmaceutical+Services+to+Manufacture+Clinical+Supply+of+Metformin+Topical+Ophthalmic+Therapy/26315373.html <p align="justify"><i>Manufacturing Agreement Advances Metformin Ophthalmology Platform Toward First-in-Human Clinical Study</i></p> <p align="justify"><strong>Palm Beach Gardens, FL, April 15, 2026 (GLOBE NEWSWIRE) -- </strong>Curative Biotechnology, Inc. (OTC: CUBT, CUBTD) (“Curative” or the “Company”), a development-stage biomedical company focused on novel therapies for degenerative eye diseases, today announced that it has engaged Sterling Pharmaceutical Services, LLC, a U.S.-based contract development and manufacturing organization (CDMO), to manufacture clinical supply of its metformin-based topical ophthalmic formulation.</p> <p align="justify">Sterling Pharmaceutical Services, LLC, located in Dupo, Illinois, specializes in formulation development and manufacturing of sterile pharmaceutical products and will support production of http://www.streetinsider.com/Press+Releases/Curative+Biotechnology+Engages+Sterling+Pharmaceutical+Services+to+Manufacture+Clinical+Supply+of+Metformin+Topical+Ophthalmic+Therapy/26315373.html Wed, 15 Apr 2026 08:08:00 -0400 A.19655944 A.25657929 CUBT CUBTD O.03307993 O.35165445 O.50535763 http://www.streetinsider.com/Press+Releases/Curative+Biotechnology+Engages+Sterling+Pharmaceutical+Services+to+Manufacture+Clinical+Supply+of+Metformin+Topical+Ophthalmic+Therapy/26315373.html <p align="justify"><i>Manufacturing Agreement Advances Metformin Ophthalmology Platform Toward First-in-Human Clinical Study</i></p> <p align="justify"><strong>Palm Beach Gardens, FL, April 15, 2026 (GLOBE NEWSWIRE) -- </strong>Curative Biotechnology, Inc. (OTC: CUBT, CUBTD) (“Curative” or the “Company”), a development-stage biomedical company focused on novel therapies for degenerative eye diseases, today announced that it has engaged Sterling Pharmaceutical Services, LLC, a U.S.-based contract development and manufacturing organization (CDMO), to manufacture clinical supply of its metformin-based topical ophthalmic formulation.</p> <p align="justify">Sterling Pharmaceutical Services, LLC, located in Dupo, Illinois, specializes in formulation development and manufacturing of sterile pharmaceutical products and will support production of http://www.streetinsider.com/Press+Releases/Curative+Biotechnology+Engages+Sterling+Pharmaceutical+Services+to+Manufacture+Clinical+Supply+of+Metformin+Topical+Ophthalmic+Therapy/26315373.html Wed, 15 Apr 2026 08:08:00 -0400 A.19655944 A.25657929 CUBT CUBTD O.03307993 O.35165445 O.50535763 http://www.streetinsider.com/Press+Releases/Curative+Biotechnology+Engages+Sterling+Pharmaceutical+Services+to+Manufacture+Clinical+Supply+of+Metformin+Topical+Ophthalmic+Therapy/26315373.html <p align="justify"><i>Manufacturing Agreement Advances Metformin Ophthalmology Platform Toward First-in-Human Clinical Study</i></p> <p align="justify"><strong>Palm Beach Gardens, FL, April 15, 2026 (GLOBE NEWSWIRE) -- </strong>Curative Biotechnology, Inc. (OTC: CUBT, CUBTD) (“Curative” or the “Company”), a development-stage biomedical company focused on novel therapies for degenerative eye diseases, today announced that it has engaged Sterling Pharmaceutical Services, LLC, a U.S.-based contract development and manufacturing organization (CDMO), to manufacture clinical supply of its metformin-based topical ophthalmic formulation.</p> <p align="justify">Sterling Pharmaceutical Services, LLC, located in Dupo, Illinois, specializes in formulation development and manufacturing of sterile pharmaceutical products and will support production of http://www.streetinsider.com/Press+Releases/Curative+Biotechnology+Engages+Sterling+Pharmaceutical+Services+to+Manufacture+Clinical+Supply+of+Metformin+Topical+Ophthalmic+Therapy/26315373.html Wed, 15 Apr 2026 08:08:00 -0400 A.19655944 A.25657929 CUBT CUBTD O.03307993 O.35165445 O.50535763 http://www.streetinsider.com/Press+Releases/Curative+Biotechnology+Engages+Sterling+Pharmaceutical+Services+to+Manufacture+Clinical+Supply+of+Metformin+Topical+Ophthalmic+Therapy/26315373.html <p align="justify"><i>Manufacturing Agreement Advances Metformin Ophthalmology Platform Toward First-in-Human Clinical Study</i></p> <p align="justify"><strong>Palm Beach Gardens, FL, April 15, 2026 (GLOBE NEWSWIRE) -- </strong>Curative Biotechnology, Inc. (OTC: CUBT, CUBTD) (“Curative” or the “Company”), a development-stage biomedical company focused on novel therapies for degenerative eye diseases, today announced that it has engaged Sterling Pharmaceutical Services, LLC, a U.S.-based contract development and manufacturing organization (CDMO), to manufacture clinical supply of its metformin-based topical ophthalmic formulation.</p> <p align="justify">Sterling Pharmaceutical Services, LLC, located in Dupo, Illinois, specializes in formulation development and manufacturing of sterile pharmaceutical products and will support production of http://www.streetinsider.com/Press+Releases/Curative+Biotechnology+Engages+Sterling+Pharmaceutical+Services+to+Manufacture+Clinical+Supply+of+Metformin+Topical+Ophthalmic+Therapy/26315373.html Wed, 15 Apr 2026 08:08:00 -0400 A.19655944 A.25657929 CUBT CUBTD O.03307993 O.35165445 O.50535763 http://www.streetinsider.com/Press+Releases/Curative+Biotechnology+Engages+Sterling+Pharmaceutical+Services+to+Manufacture+Clinical+Supply+of+Metformin+Topical+Ophthalmic+Therapy/26315373.html <p align="justify"><i>Manufacturing Agreement Advances Metformin Ophthalmology Platform Toward First-in-Human Clinical Study</i></p> <p align="justify"><strong>Palm Beach Gardens, FL, April 15, 2026 (GLOBE NEWSWIRE) -- </strong>Curative Biotechnology, Inc. (OTC: CUBT, CUBTD) (“Curative” or the “Company”), a development-stage biomedical company focused on novel therapies for degenerative eye diseases, today announced that it has engaged Sterling Pharmaceutical Services, LLC, a U.S.-based contract development and manufacturing organization (CDMO), to manufacture clinical supply of its metformin-based topical ophthalmic formulation.</p> <p align="justify">Sterling Pharmaceutical Services, LLC, located in Dupo, Illinois, specializes in formulation development and manufacturing of sterile pharmaceutical products and will support production of http://www.streetinsider.com/Press+Releases/Curative+Biotechnology+Engages+Sterling+Pharmaceutical+Services+to+Manufacture+Clinical+Supply+of+Metformin+Topical+Ophthalmic+Therapy/26315373.html Wed, 15 Apr 2026 08:08:00 -0400 A.19655944 A.25657929 CUBT CUBTD O.03307993 O.35165445 O.50535763 http://www.streetinsider.com/Press+Releases/Curative+Biotechnology+Engages+Sterling+Pharmaceutical+Services+to+Manufacture+Clinical+Supply+of+Metformin+Topical+Ophthalmic+Therapy/26315373.html <p align="justify"><i>Manufacturing Agreement Advances Metformin Ophthalmology Platform Toward First-in-Human Clinical Study</i></p> <p align="justify"><strong>Palm Beach Gardens, FL, April 15, 2026 (GLOBE NEWSWIRE) -- </strong>Curative Biotechnology, Inc. (OTC: CUBT, CUBTD) (“Curative” or the “Company”), a development-stage biomedical company focused on novel therapies for degenerative eye diseases, today announced that it has engaged Sterling Pharmaceutical Services, LLC, a U.S.-based contract development and manufacturing organization (CDMO), to manufacture clinical supply of its metformin-based topical ophthalmic formulation.</p> <p align="justify">Sterling Pharmaceutical Services, LLC, located in Dupo, Illinois, specializes in formulation development and manufacturing of sterile pharmaceutical products and will support production of http://www.streetinsider.com/Press+Releases/Curative+Biotechnology+Engages+Sterling+Pharmaceutical+Services+to+Manufacture+Clinical+Supply+of+Metformin+Topical+Ophthalmic+Therapy/26315373.html Wed, 15 Apr 2026 08:08:00 -0400 A.19655944 A.25657929 CUBT CUBTD O.03307993 O.35165445 O.50535763 http://www.streetinsider.com/Press+Releases/Curative+Biotechnology+Engages+Sterling+Pharmaceutical+Services+to+Manufacture+Clinical+Supply+of+Metformin+Topical+Ophthalmic+Therapy/26315373.html <p align="justify"><i>Manufacturing Agreement Advances Metformin Ophthalmology Platform Toward First-in-Human Clinical Study</i></p> <p align="justify"><strong>Palm Beach Gardens, FL, April 15, 2026 (GLOBE NEWSWIRE) -- </strong>Curative Biotechnology, Inc. (OTC: CUBT, CUBTD) (“Curative” or the “Company”), a development-stage biomedical company focused on novel therapies for degenerative eye diseases, today announced that it has engaged Sterling Pharmaceutical Services, LLC, a U.S.-based contract development and manufacturing organization (CDMO), to manufacture clinical supply of its metformin-based topical ophthalmic formulation.</p> <p align="justify">Sterling Pharmaceutical Services, LLC, located in Dupo, Illinois, specializes in formulation development and manufacturing of sterile pharmaceutical products and will support production of http://www.streetinsider.com/Press+Releases/Curative+Biotechnology+Engages+Sterling+Pharmaceutical+Services+to+Manufacture+Clinical+Supply+of+Metformin+Topical+Ophthalmic+Therapy/26315373.html Wed, 15 Apr 2026 08:08:00 -0400 A.19655944 A.25657929 CUBT CUBTD O.03307993 O.35165445 O.50535763 http://www.streetinsider.com/Globe+Newswire/Curative+Biotechnology+Engages+Sterling+Pharmaceutical+Services+to+Manufacture+Clinical+Supply+of+Metformin+Topical+Ophthalmic+Therapy/26315373.html <p align="justify"><i>Manufacturing Agreement Advances Metformin Ophthalmology Platform Toward First-in-Human Clinical Study</i></p> <p align="justify"><strong>Palm Beach Gardens, FL, April 15, 2026 (GLOBE NEWSWIRE) -- </strong>Curative Biotechnology, Inc. (OTC: CUBT, CUBTD) (“Curative” or the “Company”), a development-stage biomedical company focused on novel therapies for degenerative eye diseases, today announced that it has engaged Sterling Pharmaceutical Services, LLC, a U.S.-based contract development and manufacturing organization (CDMO), to manufacture clinical supply of its metformin-based topical ophthalmic formulation.</p> <p align="justify">Sterling Pharmaceutical Services, LLC, located in Dupo, Illinois, specializes in formulation development and manufacturing of sterile pharmaceutical products and will support production of http://www.streetinsider.com/Globe+Newswire/Curative+Biotechnology+Engages+Sterling+Pharmaceutical+Services+to+Manufacture+Clinical+Supply+of+Metformin+Topical+Ophthalmic+Therapy/26315373.html Wed, 15 Apr 2026 08:08:00 -0400 A.19655944 A.25657929 CUBT CUBTD O.03307993 O.35165445 O.50535763 http://www.streetinsider.com/Globe+Newswire/Curative+Biotechnology+Engages+Sterling+Pharmaceutical+Services+to+Manufacture+Clinical+Supply+of+Metformin+Topical+Ophthalmic+Therapy/26315373.html <p align="justify"><i>Manufacturing Agreement Advances Metformin Ophthalmology Platform Toward First-in-Human Clinical Study</i></p> <p align="justify"><strong>Palm Beach Gardens, FL, April 15, 2026 (GLOBE NEWSWIRE) -- </strong>Curative Biotechnology, Inc. (OTC: CUBT, CUBTD) (“Curative” or the “Company”), a development-stage biomedical company focused on novel therapies for degenerative eye diseases, today announced that it has engaged Sterling Pharmaceutical Services, LLC, a U.S.-based contract development and manufacturing organization (CDMO), to manufacture clinical supply of its metformin-based topical ophthalmic formulation.</p> <p align="justify">Sterling Pharmaceutical Services, LLC, located in Dupo, Illinois, specializes in formulation development and manufacturing of sterile pharmaceutical products and will support production of http://www.streetinsider.com/Globe+Newswire/Curative+Biotechnology+Engages+Sterling+Pharmaceutical+Services+to+Manufacture+Clinical+Supply+of+Metformin+Topical+Ophthalmic+Therapy/26315373.html Wed, 15 Apr 2026 08:08:00 -0400 A.19655944 A.25657929 CUBT CUBTD O.03307993 O.35165445 O.50535763